Navigation Links
Olympus broadens portfolio with new biliary metallic stent

CENTER VALLEY, Pa., June 1, 2009 Olympus America Inc. today expanded its medical portfolio by introducing the X-Suit NIR, a biliary metallic stent designed with exceptional anatomic conformability and superior radial support. The X-Suit NIR's proprietary NIRflex cell design provides a physician support and flexibility; both critical to help relieve the symptoms associated with pancreatic, liver and bile duct cancers.

The NIRflex advanced cell design biliary metallic stent provides flexible construction to fit the shape of any biliary duct. Constructed of Nitinol, the stent is water-jet cut and electro-polished for much greater durability. Each strut is also rounded, helping to reduce stress to the tissue and prevent damage to the bile duct and duodenal walls.

"Olympus provides the most extensive line of GI products and services in the industry," said Eric Halvorson, chief marketing officer, Medical Systems Group, Olympus America, Inc. "X-Suit is a good example of how Olympus remains dedicated to expanding its offerings and working with the world's top medical experts to provide solutions that best suit the needs of its customers and their patients."

To ensure precise placement of the stent during a therapeutic procedure, the X-Suit NIR has virtually no foreshortening. In addition, each end of the stent features five radiopaque markers that allow physicians to determine the position of the stent under an X-ray prior to deployment. A black marker is positioned at the proximal end of the stent facilitating endoscopic confirmation of the stent during deployment. The ease of deployment combined with superior radial support makes the X-Suit NIR the stent of choice for re-establishing biliary flow.


Contact: Lisa Koen
Golin/Harris International

Page: 1

Related biology news :

1. Olympus advances technology for laparo-endoscopic single-site surgery
2. Lockheed Martin Advances Biometrics Portfolio Through Cooperation Agreement With Cognitec
3. Springer expands its portfolio in plant sciences with Phytoparasitica
4. 2 carotid artery stenting studies show results comparable to AHA guidelines
5. Massive California fires consistent with climate change
6. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
7. Persistent man-made chemical pollutants found in deep-sea octopods and squids
8. Stent grafts: a better way to treat blunt trauma injuries
9. Goulbourne earns NSF award to research heart stent sensors
10. 12-month ATLANTA trial data show sustained benefit of Catania Stent
11. Persistent pollutant may promote obesity
Post Your Comments:
Related Image:
Olympus broadens portfolio with new biliary metallic stent
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
(Date:10/29/2015)... 2015 NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... a leading marketplace to discover and buy innovative ... wallet on StackSocial for this holiday season.   ... "Company"), a biometric authentication company focused on the ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
Breaking Biology Technology: